JCI insight
AML PATIENTS WITH WILDTYPE TP53 BUT DEFECTIVE TP53-MEDIATED APOPTOSIS HAVE A DISMAL SURVIVAL.
Josephine Dubois, Anthony Palmer, Darren King, Mohamed Rizk, Karan Bedi, Kerby A Shedden, Sami N Malek
Published: 202610.1172/jci.insight.197261
Abstract
The survival of patients with acute myelogenous leukemia (AML) carrying mutations in TP53 is dismal. We report the results of a detailed characterization of responses to treatment ex vivo with the MDM2 inhibitor MI219, a p53 protein stabilizer, in AM…
Preview only. Read the full abstract at the source